Equities

Amplia Therapeutics Ltd

Amplia Therapeutics Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.135
  • Today's Change0.036 / 36.36%
  • Shares traded803.53k
  • 1 Year change+65.36%
  • Beta1.1655
Data delayed at least 20 minutes, as of Sep 20 2024 07:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of AUD
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments3.399.2615
Total Receivables, Net3.181.151.84
Total Inventory------
Prepaid expenses0.070.040.03
Other current assets, total0.120.070.05
Total current assets6.751117
Property, plant & equipment, net0.100.180.01
Goodwill, net------
Intangibles, net7.947.947.94
Long term investments------
Note receivable - long term------
Other long term assets0.050.05--
Total assets151924
LIABILITIES
Accounts payable------
Accrued expenses--0.01--
Notes payable/short-term debt000
Current portion long-term debt/capital leases1.572.17--
Other current liabilities, total0.040.220.16
Total current liabilities3.402.750.53
Total long term debt0.010.092.10
Total debt1.592.272.10
Deferred income tax------
Minority interest------
Other liabilities, total0.010.000.01
Total liabilities3.432.852.64
SHAREHOLDERS EQUITY
Common stock152152152
Additional paid-in capital------
Retained earnings (accumulated deficit)(140)(134)(128)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total--(1.82)(1.82)
Total equity111622
Total liabilities & shareholders' equity151924
Total common shares outstanding200200199
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.